Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

NCT05938075 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV
SARS-CoV-2

Interventions

BIOLOGICAL: VXCO-100
BIOLOGICAL: COVID-19 mRNA vaccine

Sponsor

Vaccine Company, Inc.

Collaborators

[object Object]